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Abstract  
Background: Tamoxifen is frequently used for the treatment of hormone receptor positive breast cancer (BC). 
Mainly CYP2D6 is responsible for the transformation to therapeutically active metabolites, but CYP2C19, 
CYP2C9 and CYP2B6 also are involved. We investigated the impact of polymorphisms within the genes 
encoding these CYP enzymes on the relapse free time (RFT) in breast cancer patients.  
 
Methods: Ninety-nine hormone receptor positive breast cancer patients, who had undergone adjuvant tamoxifen 
therapy, were genotyped for seventeen common variants within the genes encoding CYP2D6, CYP2C9, 
CYP2C19, and CYP2B6 using TaqMan and PCR/RFLP technology. Kaplan-Meier and Cox regression analyses 
were performed to elucidate the impact of genetic variants on RFT. Furthermore, CYP2D6 metabolic activity 
was determined in a subset of 50 patients by assessing dextromethorphan/dextrorphan urinary excretion ratios.  
CYP2D6 activity was compared to the CYP2D6 allelic combinations to evaluate the predictive value of the 
CYP2D6 genotyping results on phenotype.  
 
Results: Although a trend towards longer RFTs in carriers of CYP2D6 allele combinations encoding for 
extensive and ultrafast metabolizer phenotypes was observed, none of the investigated genetic variants had a 
statistically significant impact on RFT. The combined analysis of five major CYP2D6 variants was useful for the 
discrimination between poor and non-poor metabolizers.  
 
Conclusions: Comprehensive CYP2D6 genotyping has a good predictive value for CYP2D6 activity. Common 
variants in CYP2C9, CYP2C19, CYP2D6 and CYP2B6 did not have a significant impact on the RFT in this 
cohort of BC patients.  
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Introduction 
Breast cancer (BC) is one of the most frequent cancers in the western world. Tamoxifen, a selective estrogen 
receptor modulator (SERM), is widely used as an efficient therapeutic option in the treatment and relapse 
prevention of estrogen receptor-positive breast cancer [12]. Tamoxifen is transformed predominantly by the drug 
metabolizing enzymes CYP3A4 and CYP2D6 into the therapeutically more efficient drug metabolites 4-
hydroxytamoxifen (4-OH-tamoxifen) and endoxifen. By binding to the estrogen receptor α (ERα) tamoxifen and 
its metabolites modulate the estrogen-induced transcription of ERα target genes. The metabolites 4-OH-
tamoxifen and endoxifen show up to 100 times higher affinity to the estrogen receptor α (ERα) than the parental 
compound [7]. As a result, the efficacy of tamoxifen strongly depends on its appropriate bioactivation by 
cytochrome P450 enzymes. CYP2D6 is highly polymorphic and shows a high interindividual variability in its 
activity. Currently, there are more than 100 genetic variants described for CYP2D6 [21]. Several genetic variants 
are known to cause an impaired enzyme activity (CYP2D6*10, *41) or to even induce a total loss of enzyme 
function (e.g. CYP2D6*4, *5, *6). Furthermore, gene duplications or multiplications of CYP2D6 that occur in 2-
3% of white individuals may lead to an exceptionally fast metabolism of CYP2D6 substrates. Genetic 
polymorphisms of CYP2D6 have been repeatedly associated with a changed therapeutic outcome in BC patients 
treated with tamoxifen. Several studies could demonstrate that genetic variants causing an impaired CYP2D6 
enzyme activity or even a loss of CYP2D6 function are associated with a shorter relapse free time (RFT) upon 
tamoxifen therapy [10, 20]. Other studies, however, showed conflicting results. Especially in studies where the 
efficacy of tamoxifen in relation to the CYP2D6 metabolizer status was tested in an adjuvant setting, no clear 
relationship between CYP2D6 status and therapeutic outcome was observed [16, 18]. The latter studies are, 
however, controversial in the literature, due to the facts that DNA was isolated from tumor tissues and not from 
blood, and that Hardy-Weinberg equilibria were partly not reached for several CYP2D6 genetic variants [14, 23]. 
Other enzymes involved in tamoxifen metabolism comprise CYP2C9, CYP2C19, and CYP2B6 [13]. These three 
enzymes are also involved in the formation of 4-OH-tamoxifen and endoxifen, but their contribution may depend 
on actual tamoxifen concentrations and on CYP2D6 activity.  
In this study, we studied the impact of genetic variants in the genes encoding the drug metabolizing enzymes 
CYP2C9, CYP2C19, CYP2B6 and CYP2D6 on the RFT in BC patients treated with tamoxifen in an adjuvant 
setting. We chose to investigate genetic variants that have been demonstrated to have a significant impact on the 
metabolic efficacy of the enzymes in focus in order to evaluate to which extent these polymorphisms might be 
suitable to predict the therapeutic outcome with tamoxifen.  
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Patients and Methods 
Patients 
Ninety-nine patients were included in this study. Patients were of Caucasian origin, diagnosed with early-stage 
estrogen receptor (ER)-positive BC and treated with adjuvant tamoxifen. Patients were recruited at the Breast 
Center Zurich, Switzerland between July 2009 and December 2012. Tumors were demonstrated to be ER 
positive in all patients and 91% had a >20% ER expression on the surface. The majority of cases also exhibited 
PR. Patients were treated with tamoxifen alone or sequentially with aromatase inhibitors (AIs) as the primary 
treatment choice. In case of a chemotherapeutic treatment (75.8%), regimens comprised the combinations FEC 
(5-fluorouracil, epirubicin and cyclophosphamide), FEC-TXT (5-fluorouracil, epirubicin, cyclophosphamide and 
docetaxel) or EC-TAX (epirubicin, cyclophosphamide and paclitaxel). Data of primary BC diagnosis and disease 
recurrence were confirmed from the patients’pathological and medical records. The study was approved by the 
local ethical committee of Zurich, and written informed consent was obtained. The demographic and disease- 
associated characteristics of all patients included in the study are shown in table 1. 
 
Genotyping 
From all patients, a whole blood sample was collected in EDTA vials. Genomic DNA was extracted using the 
QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s recommendations. 
Extracted DNA was used to genotype all patients for 17 genetic variants within the genes encoding cytochrome 
P450 enzymes involved in the metabolism of tamoxifen. The genotyping comprised the allelic variants 
CYP2C9*2 and *3, CYP2C19*2, *3, *4, *6 and *17, CYP2B6*6, *7 and *16, CYP2D6*3, *4, *5, *6, *10 and 
*41 as well as analysis of CYP2D6 gene duplications/multiplications. The majority of variants were determined 
using TaqMan SNP assay technology (Agilent Technologies, Santa Clara, CA, USA). The variant CYP2D6*41 
was analyzed using a conventional nested PCR approach followed by digestion of the PCR product with the 
restriction enzyme BsepMI. The forward primer used in the second PCR reaction carried an artificial mutation in 
the area of the 3’ end, thereby creating a functional restriction site for BsepMI in interplay with the wild type 
form at the CYP2D6*41 locus. The determination of CYP2D6 duplications/multiplications was performed as 
described previously [24]. 
Genotypes of CYP2D6 were assigned to the expected corresponding metabolizer phenotypes according to the 
evaluation system by Gaedigk et al. [8]. The genotype/phenotype assignments are summarized in table 2.    
 
 
5 
 
CYP2D6 phenotyping and CYP2D6 metabolizer type assignment 
Phenotypes predicted on the basis of CYP2D6 genotypes were compared to the CYP2D6 phenotypes measured 
in a subset of BC patients. Phenotypic data were obtained by High Pressure Liquid Chromatography (HPLC) 
according to the methods described by Abdel-Rahman et al. [1] and Blake et al. [3]. HPLC based phenotype was 
determined as follows: Six hours after the intake of 25mg dextrometorphan (DM), a prototypical CYP2D6 
substrate, the concentrations of methyl-dextrorphan (MD) and its O-demethylated metabolite dextrorphan (DX) 
were determined in the urine of 50 patients by reversed-phase HPLC with fluorescence detection. For this 
purpose, 1.25ml of each urine sample was deglucuronidated by adding 500ul phosphate buffer and 25ul 
glucuronidase. The samples were incubated at 50°C, cooled down, and subsequently centrifuged and included in 
the further analysis. The DM/DX ratios were calculated using the peak height concentrations of DM and DX, 
determined by HPLC. Patients were considered as CYP2D6 phenotypic PM, when exhibiting a DM/DX 
excretion ratio of > 0.3, as described previously [4, 25]. Furthermore, patients were evaluated as CYP2D6 
phenotypic IM, EM or UM, when showing DM/DX metabolic ratios of 0.03 - 0.3, 0.0003 – (<0.03), and 
<0.0003, respectively.     
 
Statistical analysis 
The chi-square test and the Fisher’s exact test were used to compare categorical variables, such as e.g. the 
dichotomized response measure in relation to the abundance of different genetic variants (e.g. genotype 
frequencies) or any pathological molecular markers within the patient groups. Continuous data (e.g. age or 
duration of tamoxifen/AI intake) are given as median ± STD or mean plus time range and were compared using 
the Mann-Whitney U test. The Kruskal-Wallis test was performed to compare the observed DM/DX ratios in the 
predicted CYP2D6 phenotype groups.   
The relapse free time (RFT) was determined in patients who were taking tamoxifen for at least 12 months. The 
RFT was defined as the time interval in months between the time point of BC diagnosis and the occurrence of 
the first relapse of disease. A relapse was defined as the occurrence of an event such as either metastatic disease, 
local or distant recurrence of the tumor, or a new invasive primary breast cancer. The RFT was estimated using 
the Kaplan-Meier method and statistically analyzed using the log-rank test. A two-sided p-value of < 0.05 was 
considered statistically significant. The impact of any putative confounders on RFT, such as tumor stage, 
chemotherapy, menopausal or ER status was tested performing a Cox regression analysis. The program SPSS 
(version 21, SPSS Inc., Chicago, IL, USA) was used for statistical analysis. 
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Results 
Ninety-nine patients were genotyped for 17 different polymorphisms in the genes encoding the drug 
metabolizing enzymes CYP2C9, CYP2C19, CYP2D6 and CYP2B6 using leukocytic DNA. In case of CYP2D6, 
seven different genetic variants were determined, including gene duplications/multiplications and the most 
important variants (*3, *4, *5, *6, *10, *41) responsible for an impaired enzyme activity or the expression of 
null alleles. With the exception of the mutation CYP2C19*6, all variants were in Hardy-Weinberg-equilibrium. 
The variant CYP2C19*6 appeared only once in homozygous form in the cohort and was therefore calculated to 
be in Hardy-Weinberg-dysequilibrium.  
Fifteen patients developed a relapse of breast cancer within the observational period. Table 1 demonstrates and 
compares the demographic and disease characteristics of the individuals showing a relapse with the patient group 
that stayed disease free during the time of observation. In general, no significant differences were observed when 
comparing both groups with regard to age, disease stage, grade, or menopausal status. A relapse was 
significantly less frequently observed in patients with > 20% ER expression (p<0.001, chi-square test). The 
observational period and, consequently, the average time of tamoxifen intake was significantly longer in the 
relapse free group (p<0.001 and p=0.003, respectively).   
Eighty-six patients were successfully genotyped for CYP2D6 duplications/multiplications and could, thus, be 
grouped according to their predicted CYP2D6 phenotypes based on the calculated activity scores for CYP2D6 
([9], table 2). As demonstrated in table 2 no significant differences were detected in the overall frequencies of 
predicted CYP2D6 phenotypes in relation to the relapse status. Additionally, genotype based predicted CYP2D6 
phenotypes were correlated with the experimentally confirmed phenotype (urinary DM/DX metabolic ratio) in a 
subgroup of 50 patients, where both the genotypic and phenotypic information was available. As demonstrated in 
figure 1 the metabolic DM/DX ratios differed significantly between the predicted CYP2D6 phenotypes (p = 
0.001, Kruskal-Wallis test). The prediction of phenotypes based on genotyping results was especially well 
reproducible for the discrimination between poor and non-poor metabolizers (table 3). A sensitive discrimination 
between intermediate, extensive and ultrafast metabolizers was, however, only possible to a limited extent 
(figure 1, table 3).  
All ninety-nine patients were included into the analysis investigating, to which extent the genotypes of CYP2C9, 
CYP2C19, CYP2D6 and CYP2B6 influence the relapse time in BC patients treated with tamoxifen. In several sub 
analyses, the estrogen receptor status, the menopausal state and a concomitant chemotherapeutic treatment were 
considered additional putative risk factors and were also taken into consideration. In the case of ER status, it was 
assumed that an expression degree of > 20% would be an important prerequisite for an efficient therapy 
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approach with antiestrogens, such as tamoxifen. The average duration of tamoxifen intake was 30 months (range 
of 12 to 77 months) and aromatase inhibitors 10 months (range of 0 to 64 months). The median follow-up time 
of patients was 46 months. To analyze the influence of genetic variants detected in CYP2C9, CYP2C19, 
CYP2B6, and CYP2D6 genes on the BC-RFT the following approach was adopted. First, the frequencies of 
variant carriers (heterozygous plus homozygous individuals) were compared in the relapse and relapse free 
groups before (table 4) and after a logistic regression analysis stratifying for ER density, menopausal state, 
disease grade and stage and an additional chemotherapeutic treatment. Second, the RFTs were analyzed in 
relation to the investigated genotypes using the Kaplan-Maier method without and with stratification for ER and 
menopausal status (Cox regression analysis). No significant associations were observed between CYP2C9, 
CYP2C19 and CYP2B6 genotypes and the risk for a BC relapse before or after stratification for the different 
putative confounders. The ER state appeared to be an independent risk factor for the development of a disease 
relapse: 6 of 9 patients with an ER expression below or equal to 20% had a relapse in comparison to 9 of 90 with 
an ER expression above 20% (p<0.001). As demonstrated in figure 2 a trend towards a lower relapse rate was 
observed for individuals carrying allelic combinations that induce an EM or UM genotype of CYP2D6 (p = 
0.19). This trend was repeatedly observed, when stratifying for different risk confounders.  
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Discussion 
Several studies could demonstrate that interindividual differences in the activity of CYP2D6 may affect the 
therapeutic outcome in breast cancer patients receiving tamoxifen in an adjuvant setting [19, 20]. Besides 
CYP2D6, other drug-metabolizing enzymes play a role in the in vivo transformation of tamoxifen, but were, in 
this context, rarely investigated. Therefore, our aim was to study to which extent genetic polymorphisms in 
CYP2D6, CYP2C9, CYP2C19, and CYP2B6 either alone or in interplay with each other influence the relapse risk 
under treatment with tamoxifen in a cohort of Caucasian breast cancer patients.  
Although not significant, we could show in concordance with previous studies [19, 20] that genotypes associated 
with normal or increased CYP2D6 activity lead to a favorable treatment outcome under tamoxifen, when taking 
the re-occurrence of BC as a primary endpoint. This trend towards lower relapse rates can be explained by the 
increased production of the potent metabolites 4-OH-tamoxifen and endoxifen. The variant CYP2C19*17 has 
been associated with a fast metabolizer phenotype of CYP2C19 due to an increased expression of CYP2C19 [2, 
22]. CYP2C19*17 may, thus, lead to an augmented production of 4-OH-tamoxifen, which may improve the 
treatment outcome as reported by Schroth et al. 2007 [19]. In our study, however, we did not observe an effect of 
CYP2C19*17 on treatment outcome, neither when analyzing the impact of the *17 variant on the relapse rate 
alone nor in combination with fast metabolizer genotypes of CYP2D6.  
Different genotypes of CYP2C9, CYP2C19 or CYP2B6 did not significantly alter the risk for a relapse of BC 
under treatment with tamoxifen, which underlines the stronger impact of CYP2D6 on tamoxifen 
pharmacokinetics. Of note, we used DNA from peripheral blood mononuclear cells (PBMCs) for our analysis, 
which more accurately reflects the DNA sequence of CYP genes in the liver, whereas DNA obtained from e.g. 
tumor samples may harbor additional cancer-induced mutations, as has been recently discussed [17]. 
Although several meta-analyses demonstrated that patients with CYP2D6 extensive metabolizer 
genotypes/phenotypes as compared to slow metabolizer geno- and phenotypes have a longer disease-free 
survival, the overall survival appeared not to be significantly influenced by the CYP2D6 metabolizer state in 
tamoxifen-treated BC patients. Furthermore, these studies provided inconclusive results with regard to potential 
treatment guidelines for tamoxifen based on CYP2D6 genotyping results. [11, 15, 26].  
Instead of assigning four metabolizer phenotypes to genotypes, we tested the application of the CYP2D6 
genotyping evaluation system of Gaedigk et al. [9], which weighs the impact of different CYP2D6 genotypes on 
CYP2D6 enzyme activity by assigning activity scores (AS) to the allelic combinations. By correlating predicted 
to observed CYP2D6 phenotypes, we could demonstrate that the AS system, if based on comprehensive 
CYP2D6 genotyping results, appears to be a useful approach to discriminate between slow and extensive 
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metabolizers. Phenotypic poor and intermediate metabolizers were especially well predicted. A finer 
discrimination especially between intermediate, extensive and ultrafast metabolizers is, however, not reliably 
possible based on this system. Since not all possible genetic variations in CYP2D6 were investigated in our 
study, misclassification may also arise from the assignment of the *1 allele to individuals who harbor a rare, 
activity-lowering CYP2D6 mutation. Additionally, CYP2D6 phenotyping by using urinary dextromethorphan-
based metabolite ratios may not be the optimal phenotyping tool, because small activity differences cannot be 
reliably detected [5, 6], which in turn, may also lead to misclassifications.  
Besides an estrogen-receptor expression below 20%, no other factor like demographics, menopausal state or 
chemotherapy regimen used were identified as a risk for a relapse.  
Our study includes a limited number of individuals and was performed in a retrospective manner. Both aspects 
could potentially weaken the associations between genotypes and therapeutic outcome with tamoxifen especially 
in cases, where a polymorphism might have a weak impact on the breast cancer recurrence risk. The data 
reported here should be validated in the future by e.g. the performance of prospective studies assessing the 
impact of CYP2D6 variants on the therapeutic outcome of BC in large cohorts of tamoxifen treated BC patients.  
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Table 1. Demographic information and disease characteristics of patients treated with tamoxifen for the 
treatment of breast carcinoma (% in parentheses unless stated otherwise)  
 
 All 
(n = 99) 
No relapse 
(n = 84) 
Relapse 
(n = 15) 
p valuea) 
Age (years, median, range) 48 (28-77) 48 (28-73) 50 (37-77) ns 
Stage     
     I-IIa 65 (65.7) 57 (67.9) 8 (53.3) ns 
     IIb-IIIc 34 (34.3) 27 (32.1) 7 (46.7)  
     
ER > 20% 90 (90.9) 81 (96.4) 9 (60.0) <0.001 
PR presence 84 (84.8) 75 (89.3) 9 (60.0) ns 
HER-2 positive 22 (22.2) 21 (25.0) 1 (6.7) ns 
Grade     
    1 10 (10.1) 9 (10.7) 1 (6.7)  
    2 46 (46.5) 40 (47.6) 6 (40.0) ns 
    3 43 (43.4) 35 (41.7) 8 (53.3)  
     
Observational period (months (min-max)) 47.8 (12-130) 51.6 (12-130) 26.5 (12-72) <0.001 b) 
Tamoxifen intake (months (min-max)) 30.4 (12-77) 32.3 (12-77) 19.9 (12-50) 0.003b) 
AI intake (months (min-max)) 10.3 (0-64) 9.8 (0-50) 12.9 (0-64) nsb) 
Premenopause (%) 47 (47.5) 40 (47.6) 7 (46.7) ns 
Chemotherapy (%) 75 (75.8) 63 (75.0) 12 (80.0) ns 
 
a)   Fisher’s exact tests or chi-square tests were performed. 
b)   The Mann-Whitney U test was performed 
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Table 2.  Prediction of CYP2D6 enzyme activity based on CYP2D6 genotyping results and the assignment of activity scores (AS) according to Gaedigk et al. [8, 9] 
 
 
a)   AS assignment to alleles:  
       *3, *4, *5, *6 (non functional), AS 0; *10, *41, AS 0.5 (reduced function); *1, AS 1 (wild type allele); duplication/multiplication, AS 2 (increased function) 
b)   only observed genotypes are listed 
c)   The chi-square test was applied 
 
Designation AS value assigned 
to the allelic 
combinationsa) 
Genotypesb) All 
n = 98 (%) 
No relapse 
n = 83 (%) 
Relapse 
n = 15 (%) 
p valuec) 
Poor metabolizer (PM) 0 *4/*4, *6/*6 6 (6.7) 5 (6.0) 1 (6.7) 
ns 
Intermediate metabolizer (IM) 0.5 *3/*10, *4/*10, *6/*10  
*4/*41, *6/*41,  
 
33 (33.7)  27 (32.5) 6 (40.0) 
 1 *1/*3, *1/*4, *1/*5, *1/*6, *10/*10, 
*10/*41, *41/*41  
9 (9.2)  8 (9.6) 1 (6.7) 
 1.5 *1/*10, *1/*41 20 (20.4) 18 (21.7) 2 (13.3) 
Extensive metabolizer (EM) 2 *1/*1  25 (25.5) 22 (26.5) 3 (20.0) 
Ultrarapid metabolizer (UM) >2 Duplications or multiplications  
of functional alleles  
5 (5.1) 3 (3.6) 2 (13.3) 
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Table 3.  Concordance of predicted and measured CYP2D6 phenotypes in a subset of BC patients
Genotype based predicted 
CYP2D6 phenotype 
Patients (n = 50) 
  n (%)  
Concordance 
Predicted/observed 
Observed phenotype 
(based on DM/DX ratio) 
Median               Range 
PM  3 (6) 3/4 1.803          1.490 – 5.337 
IM 36 (72) 36/32 0.097          0.004 – 0.433 
EM 8 (16) 8/13 0.016          0.000 – 0.090 
UM 3 (6) 3/1 0.021          0.016 – 0.130 
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Table 4.  Genotype frequencies of CYP2C9, CYP2C19, CYP2B6 and CYP2D6 before and after stratification for disease behavior in 99 BC patients 
a)  n denotes the absolute number of individuals carrying the respective genotype 
b) In each subgroup the abundance of CYP2D6 gene duplications/multiplications is compared (left column: not abundant, right column: abundant) 
Gene Allele 
Genotype, na) (%), all patients Genotype, n (%), relapse free group Genotype, n (%), relapse group p-value 
(variant vs. non 
variant carrier) wt het hom wt het hom wt het hom 
CYP2C9 *2 76 (76.8)   22 (22.2) 1 (1.0)  65 (77.4)  18 (21.4)  1 (1.2)  11 (73.3)  (4) 26.7  0 (0.0) ns 
 *3 85 (85.9)   13 (13.1)  1 (1.0)  70 (83.3)  13 (15.5)  1 (1.2) 15 (100)  (0) 0.0  1 (1.0) ns 
CYP2C19 *2 72 (72.7)   22 (22.2)  5 (5.1)  60 (71.4)  20 (23.8)  4 (4.8)  12 (80.0)  (2) 13.3  1 (6.7) ns 
 *3 99 (100.0)   0 (0.0)  0 (0.0)  84 (100.0)  0 (0.0)  0 (0.0)  15 (100.0)  (0) 0.0  0 (0.0) ns 
 *4 98 (99.0)   1 (1.0)  0 (0.0)  83 (98.8)  1 (1.2)  0 (0.0)  15 (100.0)  (0) 0.0  0 (0.0) ns 
 *6 98 (99.0)   0 (0.0)  1 (1.0)  83 (98.8)  0 (0.0)  1 (1.2)  15 (100.0)  (0) 0.0  0 (0.0) ns 
 *17 67 (67.7)   28 (28.3)  4 (4.0)  57 (67.9)  23 (27.4)  4 (4.8)  10 (66.7)  (5) 33.3  0 (0.0) ns 
CYP2B6 *6 54 (54.5)   40 (40.4)  5 (5.1)  46 (54.8)  34 (40.5)  4 (4.8)  8 (53.3)  (6) 40.0  1 (6.7) ns 
 *7 80 (82.5)   17 (17.5)  0 (0.0)  68 (82.9)  14 (17.1)  0 (0.0)  80 (82.5)  (17) 17.5  0 (0.0) ns 
 *16 98 (99.0)   1 (1.0)  0 (0.0)  83 (98.8)  1 (1.2)  0 (0.0)  15 (100.0)  (0) 0.0  0 (0.0) ns 
CYP2D6 *3 96 (98.0)   2 (2.0)  0 (0.0)  81 (97.6)  2 (2.4)  0 (0.0)  15 (100.0)  (0) 0.0  0 (0.0) ns 
 *4 60 (61.2)   34 (34.7)  4 (4.1)  52 (62.7)  28 (33.7)  3 (3.6)  8 (53.3)  (6) 40.0  1 (6.7) ns 
 *5 97 (98.0)   2 (2.0)  0 (0.0)  83 (98.8)  1 (1.2)  0 (0.0)  14 (93.3)  (1) 6.7  0 (0.0) ns 
 *6 93 (94.9)   4 (4.1)  1 (1.0)  78 (94.0)  4 (4.8)  1 (1.2)  15 (100.0)  (0) 0.0  0 (0.0) ns 
 *10 52 (53.1)   39 (39.8)  7 (7.1)  44 (53.0)  34 (41.0)  5 (6.0)  8 (53.3)  (5) 33.3  2 (13.3) ns 
 *41 75 (79.8)   18 (19.1)  1 (1.1)  64 (80.0)  15 (18.8)  1 (1.3)  11 (78.6)  (3) 21.4  0 (0.0) ns 
 Dupl./Multipl.b) 77 (89.5)   9 (10.5)  66 (90.4)  7 (9.6)  11 (84.6)  2 (15.4) ns 
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 Figure Legends 
 
Figure 1. CYP2D6 phenotypes were predicted on the basis of CYP2D6 activity scores, as calculated from 
CYP2D6 genotyping results. Predicted CYP2D6 phenotypes were correlated with measured CYP2D6 
phenotypes, determined on the basis of urinary DM/DX ratios. 50 patients were included, where both genotype 
and phenotype data were available. The plot represents median values with data ranges. The Kruskal-Wallis test 
detected significant differences of DM/DX ratios between the different AS score groups (p = 0.001). 
 
Figure 2.  Kaplan-Meier analyses determining and comparing the RFT in months in individuals carrying 
CYP2D6 slow metabolizer (PMs plus IMs) and fast metabolizer genotypes (EMs plus UMs), CYP2C19 wild type 
and CYP2C19*17, or CYP2B6 wild type and CYP2B6*6. Although not significant, a trend towards a more 
favourable disease outcome was observed for carriers of genotypes coding for fast metabolizer phenotypes (p = 
0.19). The comparisons in case of CYP2C19 and CYP2B6 polymorphisms were not significant (p ns).   
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